IRIDEX Corporation (Nasdaq: IRIX) today provided preliminary operational and financial results for the fourth quarter and full year ended December 29, 2018.
Highlights
- Shipped approximately 460 to 465 Cyclo G6® Glaucoma Laser Systems and 45,500 to 46,500 G6 probes in the full year 2018
- Shipped approximately 119 to 124 Cyclo G6® Glaucoma Laser Systems and a record 12,000 to 13,000 G6 probes in the fourth quarter 2018
- Total revenue for 2018 expected to be $42.1 million to $42.4 million, representing an increase of 1.3% to 2.0% over 2017
- Total revenue for the fourth quarter of 2018 expected to be $11.0 million to $11.3 million, representing an increase of 7.4% to 10.3% over the fourth quarter of 2017
“Our fourth quarter results completed an exciting year for IRIDEX. Our commercial teams continued to drive growth in Cyclo G6 placements and we shipped a record number of G6 probes in the quarter. Overall, I am encouraged by the progress we made throughout the year, as we executed on multiple fronts across the organization,” said William M. Moore, Chairman and Chief Executive Officer. “Heading into 2019, we remain focused on driving awareness and sales among a broad base of glaucoma specialists and comprehensive ophthalmologists, while continuing to innovate and advance our platform to treat the spectrum of the disease.”
These preliminary results are based on management’s initial analysis of operations for the quarter and year ended December 29, 2018 and are subject to further internal review and audit by the Company’s external auditors. IRIDEX expects to issue full 2018 financial results in early March 2019, at which time the Company plans to provide guidance for full year 2019.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.